Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Bevacizumab + Sequential Chemo in Advanced Pancreatic Cancer
NCT06393166Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhejiang Cancer Hospital. Started May 2023; status: recruiting.
02
Drugs
serplulimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06393166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393166.